Derfor bør den kliniske effekt af rivastigmin revurderes løbende, specielt hos patienter, der behandles med doser mindre end 3 mg to gange daglig.
Therefore, the clinical benefit of rivastigmine should be reassessed on a regular basis, especially for patients treated at doses less than 3 mg twice a day.